Navigation Links
Intrauterine devices can be used to treat endometrial cancer
Date:9/28/2010

Intrauterine devices, originally developed as contraceptives, can also be used to treat and cure cancer of the endometrium according to new research published online in the cancer journal, Annals of Oncology [1] today (Wednesday 29 September). The finding opens the way for young women with the disease, which affects the lining of the womb, to be treated without the need for a hysterectomy, thus preserving their fertility until they have had all the children they want.

Endometrial cancer is the sixth most common cancer in women worldwide. In 2008 there were an estimated 287,630 cases diagnosed in the world, accounting for 4.8% of all female cancers, and 74,170 deaths (2.2% of all female deaths from cancer) [2]. The usual treatment is a total hysterectomy with the removal of the womb and ovaries, but this results in the end of the woman's fertility. Sometimes it is possible for patients to be given oral hormone therapy to slow down the growth of the cancer, but systemic hormone therapy can have adverse side effects such as allergic skin rashes, nausea and vomiting, headaches and abnormal uterine bleeding.

Now, a team of researchers in Italy has conducted the first prospective clinical trial to see whether an intrauterine device (IUD) releasing the progestin hormone levonorgestrel [3], combined with a monthly injection of gonadotropin-releasing hormone (GnRH) for six months could halt and reverse the cancer's growth in women aged 40 or younger. Intrauterine levonorgestrel inhibits growth of the endometrial layer of the womb, while GnRH stops the production of oestrogen, which is the hormone that promotes the development of endometrial cancer.

Women were only eligible for the study if they had atypical endometrial hyperplasia (AEH) a precursor of endometrial cancer or early cancer that had not spread and that was confined to the inner layer of the womb, the endometrium. Between 1996 and 2009, 39 patients, aged between 20 and 40,
'/>"/>

Contact: Emma Mason (media enquiries only)
wordmason@mac.com
European Society for Medical Oncology
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Intrauterine devices reduce repeat abortions
2. SDI Reports: Nearly a Third Of Physicians Use Handheld and Smartphone Devices to Access Medical Information - Physicians Most Likely to be Using Apple iPhone
3. damaka Launches Live Video Streaming on Android and Blackberry Devices
4. Eisner USA, LLC Collaborates with Surgical Review Corp to Provide Innovative Bariatric Devices to Bariatric Surgery Center of Excellence (BSCOE) Participants
5. Rhausler Announces Record Growth of Nearly 700% for its Spinal Implant Devices
6. Damaka Delivers Advanced Sweeping™ Capability of Live Sessions Across Multiple Devices Over WiFi, 3G and 4G Networks
7. FDA Tightens Oversight of Home Medical Devices
8. Data Devices International Secures Exclusive Worldwide Distribution of the Erase-O-Matic Digital Video and Computer Tape Eraser
9. Vital functions monitored with wearable and implantable devices
10. Medical Devices Driving Up Heart Care Costs
11. Molecular Devices Relaunches with HiveMind Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 Alternatives, ... permits some patients to quit using drugs while allowing ... Adi Jaffe, the founders of Alternatives, believe that abstinence-only ... before they enter treatment and that this approach hurts ... million people in the United States need treatment for ...
(Date:6/19/2013)... St. Louis, MO (PRWEB) June 19, 2013 ... solutions organization, partnered with ARAMARK Healthcare Technologies to ... equipment management plan with savings of more than ... repair and maintenance service expenditures. , “Driving economies ... the top medical equipment management challenges facing multi-site ...
(Date:6/19/2013)... a world-leading provider of scientific, technical and medical ... of the National Osteoporosis Guideline Group (NOGG) Update ... postmenopausal women and older men in the journal ... Maturitas , the original guidelines have been ... an additional focus on the management of glucocorticoid-induced ...
(Date:6/19/2013)... Mass. (PRWEB) June 19, 2013 ... security solutions, today announced that Imprivata OneSign ® ... KLAS® 2013 Mid-Term Performance Review: Software & Services report ... KLAS laud Imprivata on the superior performance of its ... support, and they indicate that Imprivata is integral to ...
(Date:6/19/2013)... According to Transparency Market Research “Endoscopy devices Market ... Forecast, 2011 – 2017,” the global endoscopy devices market ... and is expected to reach USD 10.8 billion by ... to 2017. Flexible endoscopes formed the largest category in ... for the year 2011. , Related Report : Medical ...
Breaking Medicine News(10 mins):Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3Health News:Amerinet Partners with ARAMARK Healthcare Technologies to Help Pacific Medical Centers Save 17 Percent and Better Manage System-Wide Equipment Program 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 3
... NEW YORK, Aug. 7 Duane Reade Holdings, Inc. ... previously announced offers by its wholly-owned subsidiaries, Duane Reade Inc. ... (i) any and all of the Issuers, $210,000,000 outstanding aggregate ... 2010 (the "Floating Rate Notes") (the "FRN Offer") and (ii) ...
... , NEW YORK, Aug. 7 WebMD ... HLTH ) today announced that executives of WebMD are scheduled to ... August 12, 2009 at 1:00 p.m. ET. , , ... to a live audio broadcast of the presentation over the Internet. ...
... The poll results come on the heels of the federal government,s new H1N1 ... A poll conducted by the American Red Cross shows that while a majority ... a third of parents (39%) have received no flu information from their children,s ... http://www.newscom.c o m/cgi-bin/prnh/20090108/RedCrossLOGO ) , , ...
... government to preserve study options , FRIDAY, Aug. 7 (HealthDay ... lines are routinely used by researchers in the United States, says ... known as H1 and H9, accounted for 941 of 1,217 requests, ... stem cell lines housed at the two largest stem cell banks ...
... INDIANAPOLIS Poor communication of the outcomes of medical ... a patient,s hospital discharge is common and can lead ... A new study by researchers from the Regenstrief ... found that hospital discharge summaries are grossly inadequate at ...
... , , WASHINGTON, Aug. 7 "The differences between ... policy experts," say former Chief of Staff to the House Aging Committee ... Americans, lives." , , In an op-ed column in ... Osserman contend, "With no public option, the Senate Finance bill, developed by ...
Cached Medicine News:Health News:Duane Reade Holdings, Inc. Announces Expiration and Results of Tender Offers for Senior Secured Floating Rate Notes and Senior Subordinated Notes and Solicitation of Consents to Related Indentures 2Health News:Duane Reade Holdings, Inc. Announces Expiration and Results of Tender Offers for Senior Secured Floating Rate Notes and Senior Subordinated Notes and Solicitation of Consents to Related Indentures 3Health News:Red Cross Poll Shows Parents Still Lack H1N1 Information From Schools 2Health News:U.S. Stem Cell Research Seems to Focus on Two Lines 2Health News:Fumbled handoffs can lead to medical errors 2Health News:Ex-House Aging Committee Chief of Staff Bob Weiner Warns of Insurance Control Over Health Bill Outcome, Praises House Version, 'Disappointed' by Senate; Weiner and Policy Analyst Jordan Osserman Offer Bill's 'Prognosis' 2
(Date:6/19/2013)... , June 19, 2013 NeuroDerm, ... study in volunteers, and preliminary results from a phase ... presented at the 2013 International Congress of Parkinson,s Disease ... drug formula under development for continuous administration through a ... plasma concentrations. ND0612 has been shown in ...
(Date:6/19/2013)... 19, 2013   Life Technologies Corporation ... agreement granting Suzhou Ribo Life Sciences (Ribo) the ... in China using Life,s ... siRNA molecules in combination with Invivofectamine® Rx to ... diseases with high unmet medical need in the ...
(Date:6/19/2013)... , 19. Juni 2013 ... mit der Entwicklung von SCS microRESIST™, ... in der Beschichtung mit Parylene gelungen ... von biokompatiblem Parylene mit antimikrobiellen Eigenschaften ... schädlicher Mikroorganismen auf beschichteten medizinischen Geräten. ...
Breaking Medicine Technology:NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2
... Group Inc. (Nasdaq: WWIN ; "Winner Medical" or ... and non-woven fabric made from 100% natural PurCotton® products in ... the 2011 Brean Murray, Carret & Co. Beijing China Growth ... at the JW Marriott Hotel located at 83 Jian Guo ...
... SAN DIEGO, June 22, 2011 OncoSec Medical Incorporated ... ElectroOncology therapies to treat solid tumor cancers, announced today ... to OncoSec,s board of directors and will chair its ... For over 20 years, Dr. Maida has ...
Cached Medicine Technology:Winner Medical to Present at Brean Murray, Carret & Co. Beijing China Growth Conference 2Winner Medical to Present at Brean Murray, Carret & Co. Beijing China Growth Conference 3OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors 2OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors 3
Malaria Pf. Assay Range...
An immunochromatographic test for detection of 4 species of Plasmodium antigen ( P. falciparum , P. vivax , P. malariae , P. ovale ) in whole blood....
192 Test HRP-II Enzyme Immunoassay for the presence of Plasmodium falciparum infection....
Malaria device / strip (3 line, PAN-pLDH, P.f.-HRP2)...
Medicine Products: